Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Email

NCI’s Contributions to the Discovery of Selumetinib for Children with NF1

NCI’s Contributions to the Discovery of Selumetinib for Children with NF1. For 30 years, NCI led and supported basic, translational, and clinical research that culminated in the discovery of selumetinib as the first effective treatment for kids with neurofibromatosis type 1 (NF1) and associated tumors called plexiform neurofibromas (PNs). It started in 1990 with NF1 gene identified and ending in 2020 with FDA granting approval to selumetinib for kids.
View and Print Infographic

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “NCI’s Contributions to the Discovery of Selumetinib for Children with NF1 was originally published by the National Cancer Institute.”

Email